foxo4-dri human trial senolytic Buy 10mg | Third-Party Tested FOXO4-DRI induces keloid senescent fibroblast
FOXO4 DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53 serine 15 phosphorylation Communications Biology Cellular senescence and senolytics: the path to the clinic Nature Medicine Senolytics: from pharmacological inhibitors to immunotherapies, a promising future for patients' treatment npj Aging FOXO4 DRI: Human Trial Status, Cancer Research & Senolytic Data The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4 DRI Nature Communications Peptide Inhibitors Targeting FOXO4 p53 Interactions and Inducing Senescent Cancer Cell specific Apoptosis Journal of Medicinal Chemistry
Pay in 4 interest-free payments of $5.39 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6





